ARTICLE | Company News

Synpromics, Solid targeting DMD with transcription promoters

September 22, 2017 7:54 PM UTC

Synpromics Ltd. (Edinburgh, U.K.) will provide Solid Biosciences LLC (Cambridge, Mass.) access to muscle-selective synthetic DNA transcription promoter candidates based on Synpromics' PromPT platform which will be used to develop therapies for Duchenne muscular dystrophy (DMD).

The companies said the promoters will be evaluated in vivo and that they will “enhance” Solid’s adeno-associated virus (AAV) program. The companies declined to provide terms of the deal, but Solid spokesperson Courtney Heath told BioCentury that "Synpromics' technology has the potential to help enhance specificity, expression and gene delivery for new gene therapy candidates as the company continues to build its portfolio."...